DTIC-DOME

LOE Approaching

dacarbazine

NDAINJECTIONINJECTABLE
Approved
May 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

CLINICAL PHARMACOLOGY After intravenous administration of dacarbazine, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal…

Clinical Trials (5)

NCT06831370Phase 4Recruiting

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Started Aug 2024
124 enrolled
Hodgkin Lymphoma
NCT05922904Phase 2Active Not Recruiting

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Started Dec 2023
25 enrolled
Hodgkin Lymphoma
NCT03761095Phase 1Completed

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

Started Mar 2019
41 enrolled
Leiomyosarcoma
NCT03233347Phase 2Active Not Recruiting

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Started Oct 2017
82 enrolled
Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin Lymphoma+4 more
NCT02979522Phase 1/2Active Not Recruiting

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Started Sep 2017
59 enrolled
Hodgkin Disease